The
Company reported net losses for the three and six months ended June 30, 2026 and for the six months ended June 30, 2025. The following
potentially dilutive securities were excluded from the computation of diluted loss per share during the 2026 and 2025 periods of net
loss, as their effect would have been anti-dilutive:
Schedule of Earnings Per Share Anti-diluted
| | |
2026 | | |
2025 | |
| | |
As of June 30, | |
| | |
2026 | | |
2025 | |
| Warrants to purchase common stock | |
| 1,411,566 | | |
| 712,500 | |
| Options | |
| 2,615,195 | | |
| 2,729,568 | |
| Non-vested restricted stock unit awards | |
| 2,681,835 | | |
| - | |
| Non-vested restricted common stock | |
| 3,069,272 | | |
| 1,312,301 | |
| Shares issuable upon conversion of convertible notes | |
| 2,107,757 | | |
| - | |
| Total | |
| 11,885,625 | | |
| 4,754,369 | |
|